'Use of lipid-lowering therapy: the guidelines, the drugs or the patient?'

Area of Science:

• Cardiovascular Medicine
• Pharmacogenomics
• Metabolic Disorders

Background:

• Current dyslipidemia management relies on a step-up approach targeting LDL cholesterol thresholds.
• Statins are the cornerstone of pharmacological therapy for reducing cardiovascular events.
• Existing algorithms inadequately address phenotypic variability in dyslipidemic patients.

Purpose of the Study:

• To review current evidence in dyslipidemia therapy.
• To explore the role of cumulative exposure in treatment strategies.
• To propose initial therapeutic approaches for specific patient subgroups.

Main Methods:

• Literature review of recent evidence in dyslipidemia treatment.
• Analysis of pathophysiological mechanisms and genetic variations.
• Synthesis of data for personalized therapeutic strategies.

Main Results:

• The current therapeutic algorithm for dyslipidemias is effective but lacks personalization.
• Advancements in understanding pathophysiological mechanisms and DNA genotyping promise tailored therapies.
• Specific considerations for patients with diabetes, vasculopathy, hypertriglyceridemia, and high Lp (a) are highlighted.

Conclusions:

• Personalized, 'tailor-made' therapies for dyslipidemias are emerging.
• Integrating genetic information and understanding phenotypic variables will refine treatment.
• Future strategies will address complex lipid profiles and associated conditions more effectively.